Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
73.1 USD | +2.57% | -0.01% | +2.35% |
Feb. 27 | Ligand Pharmaceuticals' Q4 Adjusted Earnings Rise, Revenue Falls; Reaffirms 2024 Guidance | MT |
Feb. 27 | Transcript : Ligand Pharmaceuticals Incorporated, Q4 2023 Earnings Call, Feb 27, 2024 |
Financials (USD)
Sales 2024 * | 137M | Sales 2025 * | 158M | Capitalization | 1.26B |
---|---|---|---|---|---|
Net income 2024 * | 28M | Net income 2025 * | 52M | EV / Sales 2024 * | 9.19 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 8 x |
P/E ratio 2024 * |
43.7
x | P/E ratio 2025 * |
25.6
x | Employees | 58 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 94.16% |
Latest transcript on Ligand Pharmaceuticals Incorporated
1 day | +2.57% | ||
1 week | -0.01% | ||
Current month | -7.88% | ||
1 month | -18.05% | ||
3 months | +1.13% | ||
6 months | +18.92% | ||
Current year | +2.35% |
Managers | Title | Age | Since |
---|---|---|---|
Todd Davis
CEO | Chief Executive Officer | 63 | 07-02-28 |
Octavio Espinoza
DFI | Director of Finance/CFO | 53 | 22-10-31 |
President | 49 | 15-08-05 |
Members of the board | Title | Age | Since |
---|---|---|---|
John W. Kozarich
CHM | Chairman | 74 | 03-02-28 |
John LaMattina
BRD | Director/Board Member | 74 | 11-01-31 |
Stephen Sabba
BRD | Director/Board Member | 64 | 08-08-03 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.24% | 26 M€ | +0.78% | - | |
0.14% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-03-28 | 73.1 | +2.57% | 109,733 |
24-03-27 | 71.27 | +3.83% | 191,807 |
24-03-26 | 68.64 | -0.88% | 107,915 |
24-03-25 | 69.25 | -2.46% | 107,055 |
24-03-22 | 71 | -2.69% | 67,489 |
Delayed Quote Nasdaq, March 28, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+2.35% | 1.26B | |
+33.46% | 701B | |
+26.24% | 571B | |
+0.93% | 381B | |
+21.03% | 334B | |
+17.51% | 319B | |
+0.74% | 210B | |
+2.95% | 210B | |
-6.05% | 201B | |
-3.61% | 157B |